CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 21 enrolled
Drug / intervention
Yohimbine Hydrochloride +2 moredrug
Likely dose
Yohimbine Hydrochloride 54mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03670212
NCT03670212Phase 1Completed
CompareCT.gov

Neuropharmacological Investigation of Frontostriatal Network Function and Nicotine Seeking Behavior in Current Smokers

Wayne State University·interventional·Posted Sep 13, 2018·Updated Sep 13, 2018

In Brief

A Phase 1 clinical trial evaluating Yohimbine Hydrochloride, Hydrocortisone, and 1 other intervention for Cigarette Smoking. Completed, enrolled 21 participants across 1 site.

Detailed Summary

In this study, 21 non-treatment-seeking cigarette smokers were recruited to investigate the effects of acute stress on brain function and nicotine seeking/self-administration behavior.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCigarette Smoking
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 13, 2018
Enrollment StartJan 7, 2016
Primary CompletionOct 4, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.8 years ago

Interventions

Yohimbine Hydrochloridedrug

54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.

Hydrocortisonedrug

10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.

Lactose Monohydrate Powderdrug

Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).